ArticleOncology letters2026
Overexpression of EZH2 is associated with clinicopathological parameters and poor prognosis in gliomas.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Enhancer of Zeste Homolog 2 (EZH2): From Glioblastoma Biology to Potential Epigenetic Therapy.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The histone methyltransferase enhancer of zeste homolog 2 (EZH2), which is primarily localized in the nucleus, mediates Polycomb repressive complex activity by trimethylating lysine 27 of histone H3 (H3K27me3), thereby leading to transcriptional silencing. EZH2 plays a crucial role in cell proliferation, differentiation and apoptosis. Its overexpression is frequently observed in various cancers and contributes to tumor progression. A potential prognostic role for EZH2 in glioma has been suggested. The present study aimed to evaluate the clinicopathological and prognostic significance of EZH2 expression in glioma. EZH2 mRNA levels in tumor and normal tissues were assessed using the TIMER2.0 and The Cancer Genome Atlas databases. The prognostic value of EZH2 mRNA expression was analyzed using the Kaplan-Meier plotter. Immunohistochemistry was performed on 147 clinical glioma samples to evaluate EZH2 protein expression. Cox proportional hazards models and Kaplan-Meier survival curves were used to examine the associations between EZH2 expression, clinicopathological parameters and overall survival (OS). EZH2 was significantly upregulated and amplified in tumor tissues across multiple cohorts. In high-grade gliomas, elevated EZH2 expression was significantly associated with poorer OS, disease-specific survival and progression-free interval. The results of the present study indicated that EZH2 expression may serve as a valuable prognostic biomarker in glioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.